Methods of treating cancer
Drug delivery conjugates targeting PSMA-expressing cancers with 177Lu and 225Ac complexes address radiation resistance by delivering targeted DNA damage, enhancing treatment efficacy across diverse tumor types.
Patent Information
- Application Number
- KR1020267036064
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-21
- Filing Date
- 2019-09-20
- Publication Date
- 2026-11-09
AI Technical Summary
Current cancer treatments, particularly for PSMA-expressing cancers, face challenges due to radiation resistance in hypoxic zones and varying responses across different tumor types, necessitating a targeted and effective therapeutic approach.
The use of drug delivery conjugates comprising compounds I-Lu, Ia-Lu, I-Ac, and Ia-Ac, which are complexed with 177Lu and 225Ac, specifically bind to PSMA on cancer cells, allowing for targeted delivery and internalization, leveraging the different radiation types of these isotopes to address both oxygen-dependent and hypoxic tumor areas.
This approach provides targeted and effective cancer treatment by inducing both single-strand and double-strand DNA damage, enhancing treatment efficacy in PSMA-expressing cancers, including prostate cancer, by utilizing the unique radiation profiles of 177Lu and 225Ac to penetrate and damage cells effectively.
Smart Images

Figure PAT00001 
Figure PAT00002 
Figure PAT00003
Abstract
Description
Technology Field
[0001] Cross-reference of related applications
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 734,649 filed on September 21, 2018, under 35 U.S. Patent Act § 119(e), the entire disclosure of which is incorporated herein by reference.
[0004] Technology field
[0005] The present disclosure relates to drug delivery conjugates for targeted therapy. The present disclosure relates to a method for treating PSMA-expressing cancer by using a compound of the formula I-Lu or Ia-Lu and I-Ac or Ia-Ac in combination, wherein 177 Lu or 225 Ac is complexed with compounds I and Ia. The present disclosure also relates to a method for treating PSMA-expressing cancer by using a compound of the formula I-Lu or Ia-Lu and I-Ac or Ia-Ac in combination. Background Technology
[0006] Prostate-specific membrane antigen (PSMA) is a type II cell surface membrane-binding glycoprotein with a molecular weight of approximately 110 kD, comprising an intracellular portion (amino acids 1 to 18), a transmembrane domain (amino acids 19 to 43), and a broad extracellular domain (amino acids 44 to 750). While the functions of the intracellular portion and the transmembrane domain are currently considered insignificant, the extracellular domain is associated with several distinct activities. PSMA acts on the central nervous system, where it metabolizes N-acetyl-aspartyl glutamate (NAAG) to produce glutamate and N-acetyl aspartate. Therefore, it is also sometimes referred to as N-acetyl alpha-linked acid dipeptidase (NAALADase). PSMA is also sometimes referred to as folate hydrolase I (FOLH I) or glutamate carboxypeptidase (GCP II) because of its role in the proximal small intestine, where it removes γ-linked glutamate from poly-γ-glutamate-containing folates and α-linked glutamate from peptides and small molecules.
[0007] PSMA was named primarily due to its high expression levels in prostate cancer cells; however, its specific function in prostate cancer cells remains unresolved. PSMA expression is highly restricted in humans and is present only in a small number of cells in salivary gland tissue, renal tissue, the small intestine, and the large intestine. PSMA is overexpressed in malignant prostate tissue compared to other organs of the body, such as the kidneys, proximal small intestine, and salivary glands. Higher PSMA expression is associated with high-grade, metastatic, and castration-resistant disease. Tumor expression in prostate cancer is typically 100 to 1,000-fold higher. Unlike many other membrane-bound proteins, PSMA is rapidly internalized into cells with a tendency similar to cell surface-bound receptors, such as vitamin receptors. PSMA is internalized through clathrin-coated pits and can subsequently be recycled to the cell surface or transported to lysosomes. Although direct evidence for interconversion is controversial, it has been suggested that the dimeric and monomeric forms of PSMA are interconvertible. However, only the dimer of PSMA possesses enzymatic activity, while the monomer does not.
[0008] PSMA is also expressed in the neural tissues of thyroid cancer, renal clear cell carcinoma, transitional cell carcinoma of the bladder, colorectal adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorpha, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, and other tumors such as soft tissue sarcoma and breast carcinoma. These cancers exhibit diverse tumors with different histological subtypes, growth rates, and cell cycle times. In some cases, the cancer is embedded within normal tissue with varying radiation resistance. Additionally, hypoxic zones within larger deposits can also lead to radiation resistance. These and other factors are known to induce different intrinsic responses to conventional external beam radiation therapy.
[0009] Although the activity of PSMA on the cell surface of prostate cells is under investigation, the inventors have recognized herein that PSMA represents a visual target for the selective and / or specific delivery to these prostate cells of biological agents containing drug compounds or in combination with biological agents. One of these drug compounds is a compound of Formula I.
[0010]
[0011] I
[0012] In the above formula 177 Lu complexes with a compound to provide I-Lu, or 225 Ac is complexed with compound I to provide I-Ac, which is useful for cancer treatment as described in WO2015 / 055318. Compounds I-Lu and I-Ac can be prepared according to the method described in WO2015 / 055318, which is cited for the preparation of compounds I-Lu and I-Ac as described in Examples 3 and 5.
[0013] Another such drug compound is compound Ia.
[0014]
[0015] Ia
[0016] ((3S,10S,14S)-3-[(naphthalene-2-yl)methyl]-1,4,12-trioxo-1-[(1R,4S)-4-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazcyclododecane-1-yl]acetamido]methyl]cyclohexyl]-2,5,11,13-tetraazhexadecane-10,14,16-tricarboxylic acid also known) In the above formula, 177 Lu complexes with compound Ia to provide Ia-Lu, or 225Ac is complexed with a compound to provide Ia-Ac, which is useful for cancer treatment as described in WO2015 / 055318. Compounds Ia-Lu and Ia-Ac can be prepared according to the method described in WO2015 / 055318, which is cited for the preparation of compounds Ia-Lu and Ia-Ac as described in Examples 3 and 5.
[0017] Compound I or Ia can be described as a small molecule that specifically binds to PSMA (prostate-specific membrane antigen) expressed on the surface of prostate cancer cells. Compound I or Ia consists of a pharmacophore ligand, glutamate-urea-lysine; and a chelator, DOTA ( 177 Lu and 225 It may be characterized by being capable of chelating Ac); and comprising a linker that connects the ligand and the chelator. Unbound by theory, urea-based pharmacological action group ligands are believed to bind the agent to the disease site and allow it to be internalized by PSMA. Additionally, the binding of I-Lu, I-Ac, Ia-Lu, or Ia-Ac is believed to induce internalization via endocytosis, which can provide for the sustained retention of the ligand and the radioactive cargo bound thereto within the cancer cell.
[0018] Conventional radioligand therapy (RLT) used in clinical practice is for thyroid cancer 131 I, and for the treatment of bone metastasis 223 Radium or 89 It includes elements that emit alpha radiation, such as strontium.
[0019] 177Lu has a half-life of 6.7 days. It releases a combination of 0.5 MeV energy consisting of negatively charged beta particles (electrons) that move chaotically through tissues for about 20 to 80 cells or 0.5 to 2 mm, causing primarily base damage and single-strand breakage. At high doses, these lesions can interact to cause sublethal damage (SLD) or potentially lethal damage (PLD), which can escalate into irreversible fatal damage. 177 Lu also emits 113 kV and 208 kV radiation, which can be used for imaging.
[0020] 225 Ac has a half-life of 9.9 days and, in contrast, emits alpha particles with an energy of 8.38 MV. Only 0.5% of the energy is emitted as 142 kV photon emission. Therefore, most of the radiation particles carry a positive charge and are approximately 8,000 times larger than β particles. Furthermore, the energy of these particles is deposited over a relatively short distance (2 to 3 cells). As a result, dense and severe tissue damage occurs in the form of double-strand breaks, along with multiple damaged sites indicating irreversible, lethal damage. This is called High Linear Energy Transfer (LET) or high-density ionization and provides an absorbed dose 3 to 7 times greater than that of β.
[0021] Isotope 177 Lu or 225 The type of cell damage inflicted by Ac is expected to differ due to differences in the characteristics of each warhead. 177Lu is considered to provide radiation with a longer path length, so it can be effective in delivering radiation to adjacent cells. In particular, the predominance of single-strand breaks in the presence of oxygen provides an opportunity to repair sublethal (SLD) or potentially lethal (PLD) damage, offering optimal conditions for normal tissue repair. Conversely, 225 Ac delivers very powerful and high LET radiation, and the possibility of repairing normal tissue is much more limited. The radiological biological effects of alpha radiation are at least five times greater than those of beta radiation, and relative biological effectiveness (RBE) must be considered for the administered dose. 225 Using Ac therapy, the type of DNA damage applied does not require the presence of oxygen, so it will be more effective in hypoxic tumor areas. 225 A possible disadvantage of Ac therapy is that it can cause a large amount of damaging radiation that is deposited only within a short distance of 2 to 4 cells.
[0022] Another such compound is PSMA-imaging conjugate 4
[0023]
[0024] (4,6,12,19-tetraazadocosan-1,3,7-tricarboxylic acid, 22-[3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl]-5,13,20-trioxo-,(3S,7S) also known) and in the above formula 68 Ga (or similar radioactive metallic isotopes) is the subject of the literature [Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68As described in [Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23: 688-97], it is complexed into a conjugate useful for imaging cancer. PSMA imaging conjugate 4 can be prepared according to the method described in the literature [Eder, 2012], which is cited for the preparation of PSMA imaging conjugate 4 as described in the examples.
[0025] In some embodiments, the present disclosure provides a method for treating cancer in a patient requiring such treatment, comprising the step of administering a therapeutically effective amount of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac to the patient.
[0026] In some embodiments, the present disclosure provides a use of compound I-Lu or Ia-Lu in combination with compound I-Ac or Ia-Ac to treat cancer in a patient. In some embodiments, the use comprises the step of administering a therapeutically effective amount of compound I-Lu or Ia-Lu and a therapeutically effective amount of compound I-Ac or Ia-Ac to a patient.
[0027] In some embodiments, the present disclosure provides the combined use of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac in the preparation of a drug useful for treating cancer in a patient. In some aspects, the drug comprises a therapeutically effective combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0028] In some embodiments, the present disclosure provides the use of compound I-Lu or Ia-Lu in the preparation of a drug useful for treating cancer in a patient in combination with compound I-Ac or Ia-Ac. In some embodiments, the drug comprises a therapeutically effective amount of compound I-Lu or I-Lu.
[0029] In some embodiments, the present disclosure provides the use of compound I-Ac or Ia-Ac in the preparation of a drug useful for treating cancer in a patient in combination with compound I-Lu or Ia-Lu. In some aspects, the drug comprises a therapeutically effective amount of compound I-Ac or Ia-Ac.
[0030] In some embodiments, the present disclosure provides a use of compound I-Lu or Ia-Lu in the preparation of a first agent useful for treating cancer in a patient in combination with a second agent comprising compound I-Ac or Ia-Ac. In some embodiments, the first agent comprises a therapeutically effective amount of compound I-Lu or I-Lu, and the second agent comprises a therapeutically effective amount of compound I-Ac or I-Ac.
[0031] In some embodiments of these embodiments, the cancer is a PSMA-expressing cancer. In some embodiments of these embodiments, the compound is at least about 98% pure. In some embodiments, the cancer is selected from the group consisting of glioma, carcinoma, sarcoma, lymphoma, melanoma, mesothelioma, nasopharyngeal carcinoma, leukemia, adenocarcinoma, and myeloma.
[0032] In some aspects of these embodiments, cancer is lung cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, cervical cancer, cutaneous melanoma, intraocular melanoma, uterine cancer, ovarian cancer, endometrial cancer, rectal cancer, gastric cancer, colon cancer, breast cancer, triple-negative breast cancer, metastatic breast cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, non-small cell lung carcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), thyroid cancer, bladder transitional cell carcinoma, colon adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorphic, malignant melanoma, pancreatic ductal carcinoma, chronic leukemia, acute leukemia, lymphocytic lymphoma, pleural mesothelioma, bladder cancer, Burkitt lymphoma, It is selected from the group consisting of ureteral cancer, kidney cancer, renal cell carcinoma, renal pelvis carcinoma, central nervous system neoplasm, primary CNS lymphoma, spinal tumor, glioma, brainstem glioma, pituitary adenoma, and gastroesophageal junction adenocarcinoma. In some embodiments of these embodiments, the cancer is primary or secondary brain cancer. In some embodiments of these embodiments, the cancer is prostate cancer. In some embodiments of these embodiments, the cancer is metastatic prostate cancer.
[0033] In some embodiments of these embodiments, the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered in a parenteral form. In some embodiments of these embodiments, the parenteral form is selected from the group consisting of intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, and intrathecal. In some embodiments of these embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is about 2 GBq to about 13 GBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is about 4 GBq to about 11 GBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is about 5 GBq to about 10 GBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is about 6 GBq to about 9 GBq. In some embodiments of these embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 6.5 GBq to about 8.5 GBq. In some embodiments of these embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 7 GBq to about 8 GBq. In some embodiments of these embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 7.4 GBq. In some embodiments of these embodiments, the total dose of I-Lu or Ia-Lu is in the range of about 15 GBq to about 200 GBq. In some embodiments of these embodiments, the total dose of I-Lu or Ia-Lu is in the range of about 25 GBq to about 185 GBq. In some embodiments of these embodiments, the total dose of I-Lu or Ia-Lu is in the range of about 35 GBq to about 150 GBq. In some embodiments of these embodiments, the total dose of I-Lu or Ia-Lu is in the range of about 40 GBq to about 100 GBq. In some embodiments of these embodiments, the total dose of I-Lu or Ia-Lu is about 44 GBq. In some embodiments of these embodiments, the maximum duration of the targeted treatment is about 19 to 23 months.
[0034] In some embodiments of these embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 20 MBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 4 MBq to about 14 MBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq to about 10 MBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 6 MBq to about 8 MBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 4 MBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 2 MBq to about 3 MBq. In some embodiments of these embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 2.5 MBq.
[0035] In other embodiments, the method and use described herein further include the step of imaging PSMA expression by cancer. In some embodiments of these embodiments, the imaging step occurs before the administration step. In some embodiments of these embodiments, the imaging step occurs after the administration step. In some embodiments of these embodiments, imaging is performed by imaging, wherein the imaging is selected from the group consisting of SPECT imaging, PET imaging, IHC, and FISH. In some embodiments of these embodiments, imaging is performed by SPECT imaging.
[0036] In some aspects of these embodiments, the imaging step provides the patient with a PSMA ligand-imaging conjugate of Formula 2.
[0037]
[0038] 2
[0039] or includes the step of administering a pharmaceutically acceptable salt thereof, wherein R' is hydrogen, or R' is selected from the group consisting of alkyl, aminoalkyl, carboxyalkyl, hydroxyalkyl, heteroalkyl, aryl, arylalkyl and heteroarylalkyl, each of which is optionally substituted, and wherein a radionuclide is bound to the conjugate.
[0040] In some aspects of these embodiments, the imaging step is a PSMA ligand-imaging conjugate of Formula 3
[0041]
[0042] 3
[0043] Alternatively, the method comprises the step of administering a pharmaceutically acceptable salt thereof, wherein R' is hydrogen, or R' is selected from the group consisting of alkyl, aminoalkyl, carboxyalkyl, hydroxyalkyl, heteroalkyl, aryl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted, and M is a cation of a radioactive nuclide. In some embodiments of this embodiment, in the conjugate or the pharmaceutically acceptable salt thereof, M is selected from the group consisting of isotopes of gallium, isotopes of indium, isotopes of copper, isotopes of technetium, and isotopes of rhenium. In some embodiments of this embodiment, in the conjugate or the pharmaceutically acceptable salt thereof, M is an isotope of technetium.
[0044] In some aspects of these embodiments, the PSMA ligand-imaging conjugate is formula 2a
[0045]
[0046] 2a
[0047] or includes the step of administering a pharmaceutically acceptable salt thereof, wherein the radionuclide is bound to the conjugate. In some aspects of these embodiments, the PSMA ligand-imaging conjugate is of Formula 3a
[0048]
[0049] 3a
[0050] Or it is a pharmaceutically acceptable salt thereof.
[0051] In some aspects of these embodiments, the imaging step provides the patient with a PSMA ligand-imaging conjugate of Formula 4.
[0052]
[0053] 4
[0054] or includes the step of administering a pharmaceutically acceptable salt thereof, wherein the radionuclide is bound to the conjugate. In some aspects of these embodiments, the radionuclide is 68 It is Ga.
[0055] In some aspects of these embodiments, the imaging step includes the step of detecting a compound of formula I-Lu or Ia-Lu administered for therapeutic purposes.
[0056] In other embodiments, the method and use described herein further include a step of determining the patient's PSMA status by imaging. In some embodiments of these embodiments, the determination step occurs before the administration step. In some embodiments of these embodiments, the determination step occurs after the administration step. In some embodiments of these embodiments, the imaging is SPECT imaging. In some embodiments of these embodiments, the patient's PSMA status is related to a clinical benefit to the patient. In some embodiments of these embodiments, the clinical benefit is selected from the group consisting of tumor growth inhibition, stable lesions, partial response, and complete response. In some embodiments of these embodiments, the clinical benefit is a stable lesion. In some embodiments of these embodiments, a PSMA-positive lesion indicates functionally active PSMA.
[0057] In some aspects of these embodiments, the determining step is a PSMA ligand-imaging conjugate of Formula 2 to the patient.
[0058]
[0059] 2
[0060] or includes the step of administering a pharmaceutically acceptable salt thereof, wherein R' is hydrogen, or R' is selected from the group consisting of alkyl, aminoalkyl, carboxyalkyl, hydroxyalkyl, heteroalkyl, aryl, arylalkyl and heteroarylalkyl, each of which is optionally substituted, and the conjugate is coupled to a radionuclide.
[0061] In some aspects of these embodiments, the determination step is a PSMA ligand-imaging conjugate of Formula 3
[0062]
[0063] 3
[0064] or the step of administering a pharmaceutically acceptable salt thereof, wherein R' is hydrogen, or R' is selected from the group consisting of alkyl, aminoalkyl, carboxyalkyl, hydroxyalkyl, heteroalkyl, aryl, arylalkyl and heteroarylalkyl, each of which is optionally substituted, and M is a cation of a radionuclide.
[0065] In some embodiments of these embodiments, in the conjugate or its pharmaceutically acceptable salt, M is selected from the group consisting of isotopes of gallium, indium, copper, technetium, and rhenium. In some embodiments of these embodiments, in the conjugate or its pharmaceutically acceptable salt, M is an isotope of technetium. In some embodiments of these embodiments, the PSMA ligand-imaging conjugate is of Formula 2a
[0066]
[0067] 2a
[0068] or includes the step of administering a pharmaceutically acceptable salt thereof, wherein the radionuclide is bound to the conjugate.
[0069] In some aspects of these embodiments, the PSMA ligand-imaging conjugate is formula 3a
[0070]
[0071] 3a
[0072] Or it is a pharmaceutically acceptable salt thereof.
[0073] In some aspects of these embodiments, the determination step involves a PSMA ligand-imaging conjugate of Formula 4 to the patient.
[0074]
[0075] 4
[0076] or includes the step of administering a pharmaceutically acceptable salt thereof, wherein the radionuclide is bound to the conjugate. In some aspects of these embodiments, the radionuclide is 68 It is Ga.
[0077] In some aspects of these embodiments, the determination step includes the step of detecting a compound of formula I-Lu or Ia-Lu administered for therapeutic purposes.
[0078] In another embodiment, the present disclosure provides a method for treating cancer in a patient requiring such treatment, comprising the step of administering a therapeutically effective combination of compounds I-Lu and I-Ac to the patient.
[0079]
[0080] I
[0081] In the above formula 177 Lu is complexed to the compound at I-Lu, and 225 Ac is complexed with the compound in I-Ac, and An Jeong-hwan disease occurs after the combined use of compounds I-Lu and I-Ac.
[0082] In another embodiment, the present disclosure provides a method for treating cancer in a patient requiring such treatment, comprising the step of administering a therapeutically effective combination of compounds Ia-Lu and Ia-Ac to the patient.
[0083]
[0084] Ia
[0085] In the above formula 177 Lu is complexed to the compound at Ia-Lu, and 225 Ac is complexed with the compound in Ia-Ac, and An Jeong-hwan disease occurs after the combined use of compounds Ia-Lu and Ia-Ac.
[0086] In another embodiment, the present disclosure provides the use of compounds I-Lu and I-Ac in the manufacture of a drug useful for treating cancer in patients.
[0087]
[0088] I
[0089] In the above formula 177 Lu is complexed to the compound at I-Lu, and 225 Ac is complexed to the compound at Ia-Ac, and An Jeong-hwan disease occurs after the combined administration of compounds I-Lu and I-Ac. In some aspects of these embodiments, the use includes the step of administering a therapeutically effective combination of compounds I-Lu and I-Ac to a patient.
[0090] In another embodiment, the present disclosure provides the use of compounds Ia-Lu and Ia-Ac in the manufacture of a drug useful for treating cancer in patients.
[0091]
[0092] Ia
[0093] In the above formula 177 Lu is complexed to the compound at Ia-Lu, and 225 Ac is complexed to the compound in Ia-Ac, and Anjeonghwan disease occurs after the combined administration of compounds Ia-Lu and Ia-Ac. In some aspects of these embodiments, the use comprises the step of administering a therapeutically effective combination of compounds Ia-Lu and Ia-Ac to a patient.
[0094] In another embodiment, the present disclosure provides the use of compounds I-Lu and I-Ac in the manufacture of a drug useful for treating cancer in patients.
[0095]
[0096] I
[0097] In the above formula 177 Lu is complexed to compound I at Ia-Lu, and 225 Ac is complexed to compound I in I-Ac. In some embodiments, the agent comprises the therapeutically effective combination of compounds I-Lu and I-Ac.
[0098] In another embodiment, the present disclosure provides the use of compounds I-Lu and I-Ac in the manufacture of a drug useful for treating cancer in patients.
[0099]
[0100] I
[0101] In the above formula 177 Lu is complexed to the compound at I-Lu, and 225 Ac is complexed to the compound in I-Ac, and An Jeong-hwan disease occurs after concomitant administration of compounds I-Lu and Ia-Ac. In some embodiments, the agent includes the therapeutically effective concomitant administration of compounds I-Lu and I-Ac.
[0102] In another embodiment, the present disclosure provides the use of compounds Ia-Lu and Ia-Ac in the manufacture of a drug useful for treating cancer in patients.
[0103]
[0104] Ia
[0105] In the above formula 177 Lu is complexed to the compound at Ia-Lu, and 225 Ac is complexed to the compound in I-Ac. In some embodiments, the agent includes the therapeutically effective combination of compounds Ia-Lu and Ia-Ac.
[0106] In another embodiment, the present disclosure provides the use of compounds Ia-Lu and Ia-Ac in the manufacture of a drug useful for treating cancer in patients.
[0107]
[0108] Ia
[0109] In the above formula 177 Lu is complexed to compound Ia in Ia-Lu, and 225 Ac is complexed to the above compounds in Ia-Ac, and Anjeonghwan disease occurs after concomitant administration of compounds Ia-Lu and Ia-Ac. In some embodiments, the agent comprises the therapeutically effective concomitant administration of compounds Ia-Lu and Ia-Ac.
[0110] In some embodiments of these embodiments, the patient is treated with at least one prior treatment. In some embodiments of these embodiments, at least one prior treatment is selected from the group consisting of androgen axis systemic treatment, chemotherapy, surgery, radiation therapy, immunotherapy, photodynamic therapy, stem cell therapy, and hyperthermia. In some embodiments of these embodiments, at least one prior treatment is systemic treatment. In some embodiments of these embodiments, the systemic treatment is selected from the group consisting of paliphosphamide, 5-fluorouracil, capecitabine, pemetrexid, cisplatin, carboplatin, gemcitabine, paclitaxel, vinorelbine, eribulin, docetaxel, cyclophosphamide, doxorubicin, regorafinib, and combinations thereof. In some embodiments of these embodiments, the cancer is a PSMA-expressing cancer. In some embodiments of these embodiments, the compound is at least about 98% pure.
[0111] In some embodiments of these embodiments, I-Lu or Ia-Lu is administered prior to I-Ac or Ia-Ac. In some embodiments of these embodiments, I-Lu or Ia-Lu is administered prior to I-Ac or Ia-Ac on the same day. In some embodiments of these embodiments, I-Lu or Ia-Lu is administered simultaneously with I-Ac or Ia-Ac. In some embodiments of these embodiments, I-Ac or Ia-Ac is administered prior to I-Lu or Ia-Lu. In some embodiments of these embodiments, I-Ac or Ia-Ac is administered prior to I-Lu or Ia-Lu on the same day.
[0112] Specific embodiments are further described by the items listed below:
[0113] 1. A method for treating cancer in a host animal, wherein the method comprises the step of administering a therapeutically effective amount of a first compound having the formula I to a host animal in combination with a therapeutically effective amount of a second compound having the formula I.
[0114] ,
[0115] In the above formula, the compound is 177 Lu (I-Lu) is ignited;
[0116] ,
[0117] In the above formula, the compound is 225 Method of ignition with Ac (I-Ac).
[0118] 2. In the first item, the first compound is a compound of formula Ia, and
[0119]
[0120] In the above formula, the compound is 177 Method of ignition with Lu.
[0121] 3. In item 1 or 2, the second compound is a compound of formula Ia.
[0122]
[0123] In the above formula, the compound is 225 Method of ignition with Ac.
[0124] 4. In any one of items 1 to 3, the cancer is associated with the expression of prostate-specific membrane antigen (PSMA).
[0125] 5. A method in which, in any one of items 1 to 4, the cancer is selected from the group consisting of prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), thyroid cancer, renal cell carcinoma, bladder transitional cell carcinoma, colorectal adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorphic, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue sarcoma, and breast cancer.
[0126] 6. A method in which, in any one of items 1 to 5, the cancer is prostate cancer.
[0127] 7. A method in which, in any one of items 1 to 6, the cancer is metastatic castration-resistant prostate cancer (mCRPC).
[0128] 8. A method in which, in any one of items 1 to 7, the therapeutically effective amount of I-Lu or Ia-Lu is about 2 GBq to about 20 GBq.
[0129] 9. A method in which, in any one of items 1 to 8, the therapeutically effective amount of I-Lu or Ia-Lu is about 6 GBq to about 8 GBq.
[0130] 10. A method in which, in any one of items 1 to 9, the therapeutically effective amount of I-Lu or Ia-Lu is about 7.4 GBq.
[0131] 11. A method in which, in any one of items 1 to 10, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 10 MBq; or about 5 MBq to about 10 MBq; or about 5 MBq to about 7 MBq.
[0132] 12. A method in which, in any one of items 1 to 11, the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq.
[0133] 13. A method in which, in any one of items 1 to 12, a compound of the formula I-Lu or Ia-Lu is administered simultaneously with a compound of the formula I-Ac or Ia-Ac.
[0134] 14. A method according to any one of items 1 to 12, wherein a compound of formula I-Lu or Ia-Lu is administered about 1 hour before a compound of formula I-Ac or Ia-Ac; or about 12 hours before a compound of formula I-Ac or Ia-Ac; or about 24 hours before a compound of formula I-Ac or Ia-Ac; or about 48 hours before a compound of formula I-Ac or Ia-Ac; or about 72 hours before a compound of formula I-Ac or Ia-Ac.
[0135] 15. A method according to any one of items 1 to 12, wherein a compound of formula I-Ac or Ia-Ac is administered about 1 hour before a compound of formula I-Lu or Ia-Lu; or about 12 hours before a compound of formula I-Lu or Ia-Lu; or about 24 hours before a compound of formula I-Lu or Ia-Lu; or about 48 hours before a compound of formula I-Lu or Ia-Lu; or about 72 hours before a compound of formula I-Lu or Ia-Lu.
[0136] 16. The method of item 13, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0137] 17. The method of item 14, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0138] 18. The method of item 15, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0139] 19. As a compound of the chemical formula I-Lu
[0140]
[0141] In the above formula, the compound is 177 As a compound that is complexed with Lu and used in combination with a therapeutically effective amount of a compound of the chemical formula I-Ac for use in cancer treatment in patients,
[0142]
[0143] In the above formula, the compound is 225 Compounds that complex with Ac.
[0144] 20. In Item 19, the compound is a compound having the chemical formula Ia-Lu.
[0145]
[0146] In the above formula, the compound is 177 Compounds that form a complex with Lu.
[0147] 21. In Item 19, compound I-Ac is a compound having the chemical formula Ia-Ac
[0148]
[0149] In the above formula, the compound is 225 Compounds that complex with Ac.
[0150] 22. A compound in which cancer is associated with the expression of prostate-specific membrane antigen (PSMA) in any one of items 19 to 21.
[0151] 23. A compound in any one of items 19 to 22, wherein the cancer is selected from the group consisting of prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), thyroid cancer, renal cell carcinoma, bladder transitional cell carcinoma, colorectal adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorphic, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue sarcoma, and breast cancer.
[0152] 24. A compound in which the cancer is prostate cancer in any one of items 19 to 23.
[0153] 25. A compound in which the cancer is metastatic castration-resistant prostate cancer (mCRPC) in any one of items 19 to 24.
[0154] 26. A compound having a therapeutically effective amount of I-Lu or Ia-Lu of any one of items 19 to 25, ranging from about 2 GBq to about 20 GBq.
[0155] 27. A compound having a therapeutically effective amount of I-Lu or Ia-Lu of any one of items 19 to 26, of about 6 GBq to about 8 GBq.
[0156] 28. A compound having a therapeutically effective amount of I-Lu or Ia-Lu of any one of items 19 to 27, of about 7.4 GBq.
[0157] 29. A compound having a therapeutically effective amount of I-Ac or Ia-Ac of any one of items 19 to 28, of about 1 MBq to about 10 MBq; or about 5 MBq to about 10 MBq; or about 5 MBq to about 7 MBq.
[0158] 30. A compound having a therapeutically effective amount of I-Ac or Ia-Ac of about 5 MBq in any one of items 19 to 29.
[0159] 31. A compound in which, in any one of items 19 to 30, a compound of the formula I-Lu or Ia-Lu is administered simultaneously with a compound of the formula I-Ac or Ia-Ac.
[0160] 32. In any one of items 19 to 30, a compound of formula I-Lu or Ia-Lu is administered about 1 hour before a compound of formula I-Ac or Ia-Ac; or about 12 hours before a compound of formula I-Ac or Ia-Ac; or about 24 hours before a compound of formula I-Ac or Ia-Ac; or about 48 hours before a compound of formula I-Ac or Ia-Ac; or about 72 hours before a compound of formula I-Ac or Ia-Ac.
[0161] 33. In any one of items 19 to 30, a compound of formula I-Ac or Ia-Ac administered about 1 hour before a compound of formula I-Lu or Ia-Lu; or about 12 hours before a compound of formula I-Lu or Ia-Lu; or about 24 hours before a compound of formula I-Lu or Ia-Lu; or about 48 hours before a compound of formula I-Lu or Ia-Lu; or about 72 hours before a compound of formula I-Lu or Ia-Lu.
[0162] 34. A compound according to item 31, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0163] 35. A compound according to item 32, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0164] 36. A compound according to item 33, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0165] 37. Uses of compounds of the chemical formula I-Lu,
[0166]
[0167] In the above formula, the compound is 177 In the manufacture of a drug containing a therapeutically effective amount of a compound of formula I-Lu complexed with Lu, for use in combination with a therapeutically effective amount of a compound of formula I-Ac to treat cancer in a patient
[0168]
[0169] In the above formula, the compound is 225 Used for ignition with Ac.
[0170] 38. In Item 37, for use in a compound of formula I-Lu with formula Ia-Lu,
[0171]
[0172] In the above formula, the compound is 177 Used for ignition with Lu.
[0173] 39. In Item 37, for use in a compound of the formula I-Ac having the formula Ia-Ac,
[0174]
[0175] In the above formula, the compound is 225 Used for ignition with Ac.
[0176] 40. In any one of items 37 to 39, the use in which cancer is associated with the expression of prostate-specific membrane antigen (PSMA).
[0177] 41. In any one of items 37 to 40, the use is selected from the group consisting of prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), thyroid cancer, renal cell carcinoma, bladder transitional cell carcinoma, colorectal adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorphic, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue sarcoma, and breast cancer.
[0178] 42. Use in any one of items 37 to 41, wherein the cancer is prostate cancer.
[0179] 43. Use in any one of items 37 to 42, wherein the cancer is metastatic castration-resistant prostate cancer (mCRPC).
[0180] 44. An use in any one of items 37 to 43, wherein the therapeutically effective amount of I-Lu or Ia-Lu is about 2 GBq to about 20 GBq.
[0181] 45. An use in which the therapeutically effective amount of I-Lu or Ia-Lu is about 6 GBq to about 8 GBq in any one of items 37 to 44.
[0182] 46. Use in any one of items 37 to 45, wherein the therapeutically effective amount of I-Lu or Ia-Lu is about 7.4 GBq.
[0183] 47. An use in any one of items 37 to 46, wherein the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 10 MBq; or about 5 MBq to about 10 MBq; or about 5 MBq to about 7 MBq.
[0184] 48. Use in any one of items 37 to 47, wherein the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq.
[0185] 49. Use in any one of items 37 to 48, wherein a compound of the formula I-Lu or Ia-Lu is administered simultaneously with a compound of the formula I-Ac or Ia-Ac.
[0186] 50. Use in any one of items 37 to 49, wherein the compound of formula I-Lu or Ia-Lu is administered about 1 hour before the compound of formula I-Ac or Ia-Ac; or about 12 hours before the compound of formula I-Ac or Ia-Ac; or about 24 hours before the compound of formula I-Ac or Ia-Ac; or about 48 hours before the compound of formula I-Ac or Ia-Ac; or about 72 hours before the compound of formula I-Ac or Ia-Ac.
[0187] 51. Use in any one of items 37 to 50, wherein a compound of formula I-Ac or Ia-Ac is administered about 1 hour before a compound of formula I-Lu or Ia-Lu; or about 12 hours before a compound of formula I-Lu or Ia-Lu; or about 24 hours before a compound of formula I-Lu or Ia-Lu; or about 48 hours before a compound of formula I-Lu or Ia-Lu; or about 72 hours before a compound of formula I-Lu or Ia-Lu.
[0188] 52. The use according to item 49, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0189] 53. The use according to item 50, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0190] 54. The use according to item 51, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0191] 55. A composition comprising a compound of the chemical formula I-Lu,
[0192]
[0193] In the above formula, the compound is 177 A composition that is complexed with Lu and used in combination with a compound of the chemical formula I-Ac in a therapeutically effective amount for the purpose of treating cancer in a patient,
[0194]
[0195] In the above formula, the compound is 225 A composition that ignites with Ac.
[0196] 56. In item 55, as a composition in which a compound of formula I-Lu is of formula Ia-Lu,
[0197]
[0198] In the above formula, the compound is 177 A composition that ignites with Lu.
[0199] 57. In item 55, as a composition in which a compound of the formula I-Ac is of the formula Ia-Ac,
[0200]
[0201] In the above formula, the compound is 225 A composition that ignites with Ac.
[0202] 58. A composition in which, in any one of items 55 to 57, cancer is associated with the expression of prostate-specific membrane antigen (PSMA).
[0203] 59. A composition in which, in any one of items 55 to 58, the cancer is selected from the group consisting of prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), thyroid cancer, renal cell carcinoma, bladder transitional cell carcinoma, colorectal adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorphic, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue sarcoma, and breast cancer.
[0204] 60. A composition in which the cancer is prostate cancer in any one of items 55 to 59.
[0205] 61. A composition in which, in any one of items 55 to 60, the cancer is metastatic castration-resistant prostate cancer (mCRPC).
[0206] 62. A composition in which, in any one of items 58 to 61, the therapeutically effective amount of I-Lu or Ia-Lu is about 2 GBq to about 20 GBq.
[0207] 63. A composition in which, in any one of items 58 to 62, the therapeutically effective amount of I-Lu or Ia-Lu is about 6 GBq to about 8 GBq.
[0208] 64. A composition in which, in any one of items 58 to 63, the therapeutically effective amount of I-Lu or Ia-Lu is about 7.4 GBq.
[0209] 65. A composition in which, in any one of items 58 to 64, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 10 MBq; or about 5 MBq to about 10 MBq; or about 5 MBq to about 7 MBq.
[0210] 66. A composition in which the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq in any one of items 58 to 65.
[0211] 67. A composition in which, in any one of items 58 to 66, a compound of the formula I-Lu or Ia-Lu is administered simultaneously with a compound of the formula I-Ac or Ia-Ac.
[0212] 68. A composition according to any one of items 58 to 67, wherein a compound of formula I-Lu or Ia-Lu is administered about 1 hour before a compound of formula I-Ac or Ia-Ac; or about 12 hours before a compound of formula I-Ac or Ia-Ac; or about 24 hours before a compound of formula I-Ac or Ia-Ac; or about 48 hours before a compound of formula I-Ac or Ia-Ac; or about 72 hours before a compound of formula I-Ac or Ia-Ac.
[0213] 69. A composition according to any one of items 58 to 68, wherein a compound of formula I-Ac or Ia-Ac is administered about 1 hour before a compound of formula I-Lu or Ia-Lu; or about 12 hours before a compound of formula I-Lu or Ia-Lu; or about 24 hours before a compound of formula I-Lu or Ia-Lu; or about 48 hours before a compound of formula I-Lu or Ia-Lu; or about 72 hours before a compound of formula I-Lu or Ia-Lu.
[0214] 70. A composition according to item 67, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0215] 71. A composition according to item 68, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0216] 72. A composition according to item 69, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0217] 73. As a pharmaceutical agent comprising a compound of the chemical formula I-Lu
[0218]
[0219] In the above formula, the compound is 177 As a drug that is complexed with Lu and, at a therapeutically effective amount, is used in combination with a compound of the chemical formula I-Ac at a therapeutically effective amount
[0220]
[0221] In the above formula, the compound is 225 A chemical that ignites with Ac.
[0222] 74. In Item 73, as a drug having the chemical formula I-Lu, the compound having the chemical formula Ia-Lu,
[0223]
[0224] In the above formula, the compound is 177 A drug that ignites with Lu.
[0225] 75. In Item 73, as a pharmaceutical agent in which a compound of the chemical formula I-Ac is of the chemical formula Ia-Ac,
[0226]
[0227] In the above formula, the compound is 225 A chemical that ignites with Ac.
[0228] 76. A drug that provides a synergistic effect on cancer associated with the expression of prostate-specific membrane antigen (PSMA) in any one of items 73 to 75.
[0229] 77. In any one of items 73 to 76, the cancer is selected from the group consisting of prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), thyroid cancer, renal cell carcinoma, bladder transitional cell carcinoma, colorectal adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorphic, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue sarcoma, and breast cancer.
[0230] 78. A drug in which the cancer is prostate cancer in any one of items 73 to 77.
[0231] 79. A drug in which the cancer is metastatic castration-resistant prostate cancer (mCRPC) in any one of items 73 to 78.
[0232] 80. A drug having a therapeutically effective amount of I-Lu or Ia-Lu of about 2 GBq to about 20 GBq in any one of items 73 to 79.
[0233] 81. A drug having a therapeutically effective amount of I-Lu or Ia-Lu of about 6 GBq to about 8 GBq in any one of items 73 to 80.
[0234] 82. A drug having a therapeutically effective dose of I-Lu or Ia-Lu of about 7.4 GBq in any one of items 73 to 81.
[0235] 83. A preparation having a therapeutically effective amount of I-Ac or Ia-Ac of any one of items 73 to 82, of about 1 MBq to about 10 MBq; or about 5 MBq to about 10 MBq; or about 5 MBq to about 7 MBq.
[0236] 84. A drug having a therapeutically effective amount of I-Ac or Ia-Ac of about 5 MBq in any one of items 73 to 83.
[0237] 85. A drug according to any one of items 73 to 84, wherein a compound of the formula I-Lu or Ia-Lu is administered simultaneously with a compound of the formula I-Ac or Ia-Ac.
[0238] 86. A preparation according to any one of items 73 to 85, wherein a compound of formula I-Lu or Ia-Lu is administered about 1 hour before a compound of formula I-Ac or Ia-Ac; or about 12 hours before a compound of formula I-Ac or Ia-Ac; or about 24 hours before a compound of formula I-Ac or Ia-Ac; or about 48 hours before a compound of formula I-Ac or Ia-Ac; or about 72 hours before a compound of formula I-Ac or Ia-Ac.
[0239] 87. A preparation according to any one of items 73 to 86, wherein a compound of formula I-Ac or Ia-Ac is administered about 1 hour before a compound of formula I-Lu or Ia-Lu; or about 12 hours before a compound of formula I-Lu or Ia-Lu; or about 24 hours before a compound of formula I-Lu or Ia-Lu; or about 48 hours before a compound of formula I-Lu or Ia-Lu; or about 72 hours before a compound of formula I-Lu or Ia-Lu.
[0240] 88. The preparation according to item 87, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0241] 89. The preparation according to item 88, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0242] 90. The preparation according to item 89, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0243] 91. A synergistic composition comprising a therapeutically effective amount of a compound of the chemical formula I-Lu,
[0244]
[0245] In the above formula, the compound is 177 As a synergistic composition that is complexed with Lu and used in combination with a compound of the formula I-Ac in a therapeutically effective amount for the purpose of treating cancer in a patient,
[0246]
[0247] In the above formula, the compound is 225 Synergistic composition that ignites with Ac.
[0248] 92. In item 91, a synergistic composition comprising a compound of formula I-Lu with formula Ia-Lu,
[0249]
[0250] In the above formula, the compound is 177 Synergistic composition that ignites with Lu.
[0251] 93. In Item 91, as a synergistic composition in which a compound of the formula I-Ac is of the formula Ia-Ac,
[0252]
[0253] In the above formula, the compound is225 Synergistic composition that ignites with Ac.
[0254] 94. A synergistic composition in which cancer is associated with the expression of prostate-specific membrane antigen (PSMA) in any one of items 91 to 93.
[0255] 95. A synergistic composition according to any one of items 91 to 94, wherein the cancer is selected from the group consisting of prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), thyroid cancer, renal cell carcinoma, bladder transitional cell carcinoma, colorectal adenocarcinoma, neuroendocrine carcinoma, glioblastoma pleomorphic, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue sarcoma, and breast cancer.
[0256] 96. A synergistic composition in which the cancer is prostate cancer in any one of items 91 to 95.
[0257] 97. A synergistic composition in which, in any one of items 91 to 96, the cancer is metastatic castration-resistant prostate cancer (mCRPC).
[0258] 98. A synergistic composition in which, in any one of items 91 to 97, the therapeutically effective amount of I-Lu or Ia-Lu is about 2 GBq to about 20 GBq.
[0259] 99. A synergistic composition in which, in any one of items 91 to 98, the therapeutically effective amount of I-Lu or Ia-Lu is about 6 GBq to about 8 GBq.
[0260] 100. A synergistic composition according to any one of items 91 to 99, wherein the therapeutically effective amount of I-Lu or Ia-Lu is about 7.4 GBq.
[0261] 101. A synergistic composition in which, in any one of items 91 to 100, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 10 MBq; or about 5 MBq to about 10 MBq; or about 5 MBq to about 7 MBq.
[0262] 102. A synergistic composition in which the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq in any one of items 91 to 101.
[0263] 103. A synergistic composition in which, in any one of items 91 to 102, a compound of the formula I-Lu or Ia-Lu is administered simultaneously with a compound of the formula I-Ac or Ia-Ac.
[0264] 104. A synergistic composition according to any one of items 91 to 103, wherein a compound of formula I-Lu or Ia-Lu is administered about 1 hour before a compound of formula I-Ac or Ia-Ac; or about 12 hours before a compound of formula I-Ac or Ia-Ac; or about 24 hours before a compound of formula I-Ac or Ia-Ac; or about 48 hours before a compound of formula I-Ac or Ia-Ac; or about 72 hours before a compound of formula I-Ac or Ia-Ac.
[0265] 105. A synergistic composition according to any one of items 91 to 104, wherein a compound of formula I-Ac or Ia-Ac is administered about 1 hour before a compound of formula I-Lu or Ia-Lu; or about 12 hours before a compound of formula I-Lu or Ia-Lu; or about 24 hours before a compound of formula I-Lu or Ia-Lu; or about 48 hours before a compound of formula I-Lu or Ia-Lu; or about 72 hours before a compound of formula I-Lu or Ia-Lu.
[0266] 106. A synergistic composition according to item 103, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu once a week for about 1 to about 7 cycles after administration of I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0267] 107. A synergistic composition according to item 104, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0268] 108. A synergistic composition according to item 105, further comprising administering a therapeutically effective amount of a compound of formula I-Lu or Ia-Lu for about 1 to about 7 cycles once a week after administration of both I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0269] definition
[0270] As used herein, “functionally active PSMA” refers to a cell surface membrane-binding glycoprotein that binds to a PSMA ligand. It will be apparent to those skilled in the art that PSMA ligands, such as those described in U.S. Patent Publication No. US 2010 / 0324008 A1 incorporated herein by reference, are well known.
[0271] As used herein, "clinical benefit" means a patient's response to treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac, which includes, among other clinical benefits defined by the U.S. Food and Drug Administration, the patient's overall survival, the ability to receive four or more cycles of treatment with I-Lu or Ia-Lu and I-Ac or Ia-Ac (e.g., four weeks of treatment), inhibition of tumor growth, stable lesions, partial response, and / or complete response.
[0272] "Inhibition of tumor growth" as used herein means a reduction in tumor size, complete disappearance of the tumor, or growth of the patient's tumor size to less than 30% during a course of treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0273] As used herein, "stable disease" refers to the absence of physical progression of the disease in a patient during a course of treatment with the combined use of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0274] The term "partial response" as used here means a reduction in tumor size of 30% or more in patients treated with a combination of I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0275] "Complete response" as used herein means that detectable disease is eliminated in patients treated with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac.
[0276] "Prior treatment" means that the patient has been treated with at least one prior treatment known in the art. It will be apparent that the prior treatment may be any treatment known to those skilled in the art, and includes, but is not limited to, chemotherapy, surgery, radiation therapy, immunotherapy, photodynamic therapy, stem cell therapy, hyperthermia, etc. The prior treatment may include systemic treatments, including, but not limited to, abiraterone, oteronel, galterone, seviteronel, apalutamide, enzalutamide, paliphosphamide, 5-fluorouracil, capecitabine, pemetrexid, cisplatin, carboplatin, gemcitabine, paclitaxel, vinorelbine, eribulin, docetaxel, cyclophosphamide, doxorubicin, regorafinib, and combinations thereof.
[0277] As used herein, the term "alkyl" comprises a chain of optionally branched carbon atoms. In certain embodiments, the alkyl advantageously has a limited length and is C1-C 24 , C1-C 12It will be further understood that they include C1-C8, C1-C6, and C1-C4. For example, these particularly limited-length alkyl groups, including C1-C8, C1-C6, and C1-C4, may be referred to as lower alkyls. It is acknowledged that the shorter the alkyl, alkenyl, and / or alkynyl group, the lower the lipid affinity for the compound and thus the different pharmacokinetic behavior. In some embodiments, in each case, the reference to alkyl will be understood to refer to the alkyl as described herein, and optionally lower alkyls. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, heptyl, octyl, etc. The "carboxyalkyl" group as used herein includes a combination of an "alkyl" group and a "carboxy" group as described herein. The "hydroxyalkyl" group as used herein includes a combination of an "alkyl" group and a "hydroxy" group as described herein. The "aminoalkyl" group as used herein includes a combination of an "alkyl" group and an "amino" group as described herein.
[0278] As used herein, the term "heteroalkyl" comprises a chain of atoms containing both carbon and at least one heteroatom, which is optionally branched. Exemplary heteroatoms include nitrogen, oxygen, and sulfur. In certain variations, exemplary heteroatoms also include phosphorus and selenium.
[0279] As used herein, the term "aryl" comprises monocyclic and polycyclic aromatic carbocyclic groups having 6 to 14 cyclic carbon atoms, each of which may be optionally substituted. Exemplary aromatic carbocyclic groups described herein include, but are not limited to, phenyl, naphthyl, etc. As used herein, the term "heteroaryl" comprises aromatic heterocyclic groups having 5 to 10 cyclic atoms, each of which may be optionally substituted. Exemplary aromatic heterocyclic groups include, but are not limited to, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, quinolinyl, quinazolinyl, quinoxalinyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, benzisosoxazolyl, benzisothiazolyl, etc. The term "heteroarylalkyl" as used herein includes a combination of an "alkyl" group described herein and a "heteroaryl" group described herein. The term "arylalkyl" as used herein includes a combination of an "alkyl" group described herein and an "aryl" group described herein, e.g., a benzyl group.
[0280] As used herein, the term “optionally substituted” comprises substituting a hydrogen atom on an optionally substituted radical with another functional group. Such other functional groups include, but are not limited to, amino, hydroxyl, halo, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, nitro, sulfonic acids and their derivatives, carboxylic acids and their derivatives, etc. For example, any of amino, hydroxyl, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, and / or sulfonic acids are optionally substituted.
[0281] As used herein, the term “administering” comprises all means of introducing the compound I-Lu or Ia-Lu and the combination of I-Ac or Ia-Ac and / or the PSMA ligand-imaging conjugate described herein into a patient, including but not limited to oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, cheek, ocular, sublingual, vaginal, rectal, etc. The compound I-Lu or Ia-Lu and the combination of I-Ac or Ia-Ac and / or the PSMA ligand-imaging conjugate described herein may be administered in a unit dosage form and / or in formulations containing conventional non-toxic, pharmaceutically acceptable carriers, adjuvants, and vehicles.
[0282] As used herein, "becquerel" refers to the SI-derived unit of radioactivity as commonly understood by those skilled in the art. One becquerel is defined as the activity of the amount of radioactive material when one nucleus decays per second. Thus, the becquerel is equivalent to the inverse second, s⁻¹. The becquerel is known to those skilled in the art as the successor to the curie (Ci), an older non-SI unit of radioactivity based on the activity of one gram of radium-226. The curie is defined as 3.7. 10¹⁰ s⁻¹, or 37 GBq.
[0283] As used herein, "Curie" or "Ci" refers to a unit of radioactivity named after the French physicist and chemist Marie Curie, as commonly understood by those skilled in the art. The prefixes milli and micro are derived from the metric system and represent 0.001 and 0.000001, respectively. Thus, a millicurie (mCi) is 0.001 curie. A microcurie (μCi) is 0.000001 curie. Specific details for implementing the invention
[0284] The embodiments of the numbered items provided in the summary above, or any combination thereof, are considered in combination with any embodiments described in the detailed description of this patent application.
[0285] Referring to FIG. 1, the method design can be described according to the presented schematic diagram. In some embodiments, the stratification factor for the design is serum lactate dehydrogenase (LDH) (< / = 260 IU / L v. > 260 IU / L), presence of liver metastasis, ECOG score (0-1 v. 2), inclusion of NAAD in best adjuvant therapy / best standard therapy regimen, etc., are included but not limited thereto. In some embodiments, the primary endpoint may be overall survival. In some embodiments, secondary endpoints include but not limited to radiographic progression-free survival (rPFS), RECIST response, time to first symptomatic skeletal event (SSE), etc. In some embodiments, additional secondary endpoints include, but are not limited to, safety and tolerability, heather-related quality of life (HRQoL; EQ-5D-5L, FACT-P, and Brief Pain Inventory - Short FORM [BPI-SF]), health economics, progression-free survival (PFS) (radiological, clinical, or PSA progression), and biochemical responses, e.g., PSA levels, alkaline phosphatase levels, and / or lactate dehydrogenase levels. In some embodiments, the endpoint of the treatment method described herein may be a patient who achieved a reduction of > / =50% from a criterion confirmed by a second treatment PSA measurement > / =4 weeks. In some embodiments, the endpoint of the treatment described herein may be a patient who achieved a reduction of > / =40% from a criterion confirmed by a second treatment PSA measurement > / =4 weeks. In some embodiments, the endpoint for the treatment method described herein may be a patient who has achieved a reduction of > / =30% from the criterion confirmed by a second treatment PSA measurement > / =4 weeks.
[0286] In one embodiment, the method described herein may be used for both human chronic drug and veterinary applications. Accordingly, a “patient” may be administered the compound I-Lu or Ia-Lu described herein, and the combination of I-Ac or Ia-Ac and / or the PSMA ligand-imaging conjugate, and may be a human, or in the case of veterinary applications, an experimental, agricultural, livestock, or wild animal. In one embodiment, the patient may be a human, an experimental animal, e.g., a rodent (e.g., mouse, rat, hamster, etc.), a rabbit, a monkey, a chimpanzee, a livestock animal, e.g., a dog, a cat, and a rabbit, an agricultural animal, e.g., a cow, a horse, a pig, a sheep, a goat, and a captive wild animal, e.g., a bear, a panda, a lion, a tiger, a leopard, an elephant, a zebra, a giraffe, a gorilla, a dolphin, and a whale.
[0287] In some embodiments, patients with PSMA-positive scans are randomized in a 2:1 ratio to receive the best adjuvant therapy / best standard therapy in combination with compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac, or only the best adjuvant therapy / best standard therapy. In some embodiments, the best adjuvant therapy / best standard therapy may be determined in consultation with medical staff / researchers. In some embodiments, the best adjuvant therapy / best standard therapy may be determined in consultation with medical staff / researchers, but agents under investigation, cytotoxic chemotherapy, other whole-body radioisotopes, and hemi-body radiation therapy will be excluded. In some embodiments, novel androgen axis drugs [NAADs], such as abiraterone or enzalutamide, are permitted.
[0288] In some embodiments, the patient will be monitored for survival, disease progression, and adverse effects over a treatment period of 6 to 10 months. In some embodiments, the long-term follow-up period may include survival and treatment updates, evaluation of adverse effects, as well as a collection of blood for hematological and chemical tests.
[0289] In some embodiments, the patient is 18 years of age or older. In some embodiments, the patient is male. In some embodiments, the patient was previously diagnosed with prostate cancer. In some embodiments, the patient was previously diagnosed with metastatic castration-resistant prostate cancer (mCRPC). In some embodiments, the patient has an Eastern Cooperative Oncology Group (ECOG) status of 0 to 2; a life expectancy of at least 6 months; histological, pathological, and / or cytological confirmation of prostate cancer; benign 68Ga-PSMA-11 PET / CT scan; previous orchiectomy and / or ongoing androgen deprivation therapy and castration levels of serum testosterone (< 50 ng / dL or < 1.7 nmol / L); previous administration of at least one NAAD, e.g., enzalutamide and / or abiraterone; previous treatment with at least one or two previous taxane regimens, said taxane regimens comprising two cycles of minimal exposure to taxane, or previous treatment with a single taxane regimen, a. the patient is unwilling to receive a second taxane regimen, or b. the patient's medical staff satisfies one or more criteria selected from the group consisting of: e.g., geriatric or health status assessment or intolerance; progressive mCRPC, e.g., at least one criterion, e.g., a. progression of serum PSA defined as two consecutive increases in PSA compared to a previous reference value measured at least one week prior to the minimum onset value of 2.0 ng / mL, b. soft-tissue progression defined as a ≥ 20% increase in the sum of the diameters (short axis for nodular lesions, long axis for non-nodular lesions) of all target lesions (SOD) based on the minimum SOD since the initiation of treatment or the appearance of one or more new lesions; and c. documented advanced mCRPC based on bone disease, e.g., progression of disease or new bone lesion(s) as assessed by bone scan (2+2 PCWG3 criteria); at least one metastatic lesion present on reference CT, MRI, or bone scan imaging obtained ≤ 28 days prior to the initiation of treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac; ≤ Grade 2 recovery from any clinically significant toxicity associated with previous treatment, e.g., previous chemotherapy, radiation, immunotherapy; adequate organ function, e.g., a. white blood cell (WBC) count ≥ 2.5 x 10⁹ / L (2.5 x 10⁹ / L is 2.5 x 10⁹ 3 / μL and 2.5 x K / μL and 2.5 x 10 3 (equivalent to / cumm and 2500 / μL) or absolute neutrophil count (ANC) ≥ 1.5 x 10 9 / L(1.5 x 10 9 / L is 1.5 x 10 3 / μL and 1.5 x K / μL and 1.5 x 10 3 Bone marrow reserves including / cumm and equivalent to 1500 / μL), platelets ≥ 100 x 10^9 / L (100 x 10^9 / L is equivalent to 100 x 10^3 / μL and 100 x K / μL and 100 x 10^3 / cumm and 100,000 / μL), and / or hemoglobin ≥ 9 g / dL (9 g / dL is equivalent to 90 g / L and 5.59 mmol / L); b. Hepatic, e.g., total bilirubin ≤ 1.5 x institutionalized upper limit of normal (ULN) (for patients with known Gilbert's syndrome, ≤ 3 x ULN is allowed), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0 x ULN or ≤ 5.0 x ULN, and renal, e.g., serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL / min; albumin > 3.0 g / dL (3.0 g / dL is equivalent to 30 g / L); and due to fragility assessed by stable bisphosphonate or denosumab for ≥ 30 days prior to treatment, he is considered unfit to receive second taxane therapy.
[0290] In some embodiments, prior treatment by the patient with strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, or hemi-body radiation within about 6 months prior to treatment; prior PSMA-targeted radioligand treatment; prior systemic anticancer treatment within about 28 days prior to treatment (e.g., chemotherapy, immunotherapy, or biological treatment [including monoclonal]); prior administration of the agent under investigation within about 28 days prior to treatment; known hypersensitivity to a component of the treatment or an analogue thereof; any other concomitant cytotoxic chemotherapy, immunotherapy, radioligand treatment, or treatment under investigation; blood transfusion within about 30 days of treatment; history of CNS metastasis in which treatment (surgery, radiation therapy, Gamma Knife) was received, is neurostable, asymptomatic, and has not been administered corticosteroids for the purpose of maintaining neurologic integrity; superscan as shown in the reference bone scan; A patient may not receive treatment if they have one or more of the following: New York Heart Association Class III or IV congestive heart failure, a history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other significant co-morbid conditions that, in the researcher's opinion, would impair treatment or cooperation; or have been diagnosed with another malignancy that is expected to alter life expectancy or interfere with disease assessment.
[0291] In various embodiments, the cancer described herein may be a tumorigenic population of cancer cells including benign and malignant tumors, or the cancer may be non-tumorigenic. The cancer may occur spontaneously, or may occur through processes such as when mutations are present in the patient's germ cells or through somatic mutations, or the cancer may be chemically, virally, or radiation-induced. Cancers applicable to the present invention described herein include, but are not limited to, gliomas, carcinomas, sarcomas, lymphomas, melanomas, mesotheliomas, nasopharyngeal carcinomas, leukemias, adenocarcinomas, and myelomas.
[0292] In some modalities, cancer is lung cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, cervical cancer, cutaneous melanoma, intraocular melanoma, uterine cancer, ovarian cancer, endometrial cancer, rectal cancer, gastric cancer, colon cancer, breast cancer, triple-negative breast cancer, metastatic breast cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, non-small cell lung cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic leukemia, acute leukemia, lymphocytic lymphoma, pleural mesothelioma, bladder cancer, Burkitt lymphoma, ureteral cancer, kidney cancer, renal cell carcinoma, renal pelvis carcinoma, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal tumor, glioma, brainstem glioma, pituitary adenoma, and gastroesophageal junction. It could be an adenocarcinoma.
[0293] Compound Ia has the chemical formula Ia
[0294]
[0295] Ia
[0296] In the above formula 177 Lu is complexed with the compound at Ia-Lu, and 225 Ac forms a complex with the compound in Ia-Ac.
[0297] In other embodiments, any various PSMA ligand-imaging conjugates detectable by PET imaging, SPECT imaging, etc. may be used. The exact method of imaging is not limited to the imaging agents described herein. Collectively, the PSMA ligand-imaging conjugates useful for imaging described herein include those described by the chemical formula and agents useful for PET imaging, SPECT imaging, etc., and are referred to as "PSMA ligand-imaging conjugates."
[0298] In one embodiment, the compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac and / or PSMA ligand-imaging conjugates described herein bind to PSMA expressed on cancer cells. In one exemplary embodiment, the compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac and / or PSMA ligand-imaging conjugates may bind differentially to PSMA on cancer cells compared to normal cells, due to differential expression (or over-expression) of PSMA on cancer cells.
[0299] In some embodiments, the compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac and PSMA ligand-imaging conjugates described herein may be administered as formulations in combination with one or more pharmaceutically acceptable carriers. In some aspects of these embodiments, the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac may be co-formulated. In some aspects of these embodiments, the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac will be administered individually as formulation agents. The carrier may be an excipient. The choice of carrier will depend significantly on factors such as the specific mode of administration, the effect of the carrier on solubility and stability, and the characteristics of the administration form. Pharmaceutical compositions suitable for the delivery of the combination of the compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac and PSMA ligand-imaging conjugates described herein and methods for their preparation are well known to those skilled in the art. These compositions and methods for their preparation can be found, for example, in the literature incorporated herein by reference [Remington: The Science & Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005)].
[0300] In one exemplary embodiment, the pharmaceutically acceptable carrier comprises any solvent, dispersion medium, coating, antibacterial and antifungal agents, isotonic agents and absorption retardants, etc., and physiologically compatible combinations thereof. In some embodiments, the carrier is suitable for parenteral administration. The pharmaceutically acceptable carrier comprises a sterile aqueous solution or dispersion and a sterile powder for the improvisational preparation of a sterile injectable solution or dispersion. A supplementary active compound may also be included in the composition of the present invention.
[0301] In various embodiments, liquid formulations may include suspensions and solutions. These formulations may include a carrier, e.g., water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifiers and / or suspending agents. Liquid formulations may also be prepared by the reconstitution of solids.
[0302] In one embodiment, the aqueous suspension may contain an active substance by mixing with a suitable excipient. Such excipients are suspending agents, e.g., sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, and acacia gum; dispersants or wetting agents, e.g., lecithin, which may be naturally occurring phosphatidides; condensation products of alkylene oxide and fatty acids, e.g., polyoxyethylene stearate; condensation products of ethylene oxide and long-chain aliphatic alcohols, e.g., heptadecaethyleneoxycetanol; condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol, e.g., polyoxyethylene sorbitol monooleate; Or a condensation product of partial esters derived from ethylene oxide, fatty acids, and hexitol anhydride, e.g., polyoxyethylene sorbitan monooleate. The aqueous suspension may also contain one or more preservatives, e.g., ascorbic acid, ethyl, n-propyl, or p-hydroxybenzoate; or one or more coloring agents.
[0303] In one exemplary embodiment, a dispersible powder and granules suitable for preparing an aqueous suspension by the addition of water are provided by mixing an active ingredient with a dispersant or wetting agent, a suspending agent, and one or more preservatives. Additional excipients, for example, coloring agents may also be present.
[0304] Suitable emulsifiers may be naturally occurring gums, e.g., acacia gum or tragacanth gum; naturally occurring phosphatides, e.g., soybean lecithin; and esters comprising a partial ester derived from a fatty acid and hexitol anhydride, e.g., sorbitan monooleate, and a condensation product of said partial ester and ethylene oxide, e.g., polyoxyethylene sorbitan monooleate.
[0305] In other embodiments, an isotonic agent, e.g., sugar, polyalcohol, e.g., mannitol, sorbitol, or sodium chloride, may be included in the composition. Extended absorption of the injectable composition may be achieved by including an absorption-delaying agent, e.g., monostearate salt and gelatin, in the composition.
[0306] Exemplary formulations for oral administration include tablets, capsules, elixirs, syrups, etc.
[0307] A wide range of acceptable dosages are considered herein, including dosages ranging from about 1 MBq to about 4 MBq of I-Ac or Ia-Ac, depending on the type of cancer described herein, the route of administration, and / or whether the compound I-Lu or Ia-Lu and I-Ac or Ia-Ac and / or PSMA ligand-imaging conjugate are administered locally or systemically. In some embodiments, acceptable dosages are considered herein in units of GBq, which include dosages ranging from about 2 GBq to about 13 GBq. Doses may be single or divided and may be administered by a wide variety of protocols, including qd, bid, tid, or even every other day, twice a week (biw: biweekly), once a week, once a month, once a quarter, etc. In each of these cases, the therapeutic effective dose described herein is understood to correspond to administration at the instance of administration, or alternatively, in total, once daily, once weekly, once monthly, or once quarterly, as determined by the administration protocol. In some embodiments, the combination of formulas I-Lu or Ia-Lu and I-Ac or Ia-Ac may be administered on an independent schedule, such as once, once weekly, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.
[0308] In one embodiment, the combination of the compound I-Lu or Ia-Lu described herein and the I-Ac or Ia-Ac or PSMA ligand-imaging conjugate may be administered directly into the bloodstream, into the muscle, or into an internal organ. Routes suitable for such parenteral administration include intravenous, intra-arterial, intraperitoneal, intrathecal, epidural, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, and subcutaneous delivery. Means suitable for parenteral administration include needle (including microneedle) syringes, needleless syringes, and infusion techniques.
[0309] In one exemplary embodiment, the parenteral formulation is typically an aqueous solution that may contain a carrier or excipient, such as a salt, a carbohydrate, and a buffer (preferably a pH of 3 to 9), but for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dry form to be used with a suitable vehicle, such as a sterile pyrogen-free substance. In other embodiments, any liquid formulation described herein may be suitable for parenteral administration of the I-Lu or Ia-Lu and I-Ac or Ia-Ac or PSMA ligand-imaging conjugates described herein. The preparation of the parenteral formulation under sterile conditions, for example, by lyophilization under sterile conditions, can be easily achieved using standard pharmaceutical techniques well known to those skilled in the art. In one embodiment, the solubility of the compound I-Lu or Ia-Lu used in the preparation of the parenteral formulation, and the combination of I-Ac or Ia-Ac or PSMA ligand-imaging conjugate, can be increased by the use of appropriate formulation techniques, such as the inclusion of a solubility-improving agent.
[0310] In various embodiments, formulations for parenteral administration may be formulated for immediate and / or modified release. In one exemplary embodiment, the active agent of the present invention (i.e., compounds I-Lu or Ia-Lu, and I-Ac or Ia-Ac or PSMA ligand-imaging conjugates) may be administered in a time-release formulation, for example, in a composition comprising a slow-release polymer. Compounds I-Lu or Ia-Lu, and I-Ac or Ia-Ac or PSMA ligand-imaging conjugates may be prepared with a carrier (including implants and microencapsulated delivery systems) to protect compounds I-Lu or Ia-Lu, and I-Ac or Ia-Ac or PSMA ligand-imaging conjugates against a rapid-release formulation, such as a controlled-release formulation. Biodegradable biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyautoesters, polylactic acid, and polylactic-polyglycolic copolymers (PGLA), may be used. Methods for preparing such formulations are generally known to those skilled in the art. In other embodiments, a composition comprising compound I or PSMA ligand-imaging conjugate compound I-Lu or Ia-Lu and I-Ac or Ia-Ac or PSMA ligand-imaging conjugate, or compound I-Lu or Ia-Lu and I-Ac or Ia-Ac or PSMA ligand-imaging conjugate described herein, may be administered continuously where appropriate.
[0311] In one embodiment, a kit is provided. When compound I-Lu or Ia-Lu, and I-Ac or Ia-Ac and PSMA ligand-imaging conjugate are administered in combination, two or more pharmaceutical compositions may be combined in the form of a kit suitable for sequential administration or combination administration of the compositions. Such a kit comprises two or more separate pharmaceutical compositions, at least one of which contains the compound I-Lu or Ia-Lu and I-Ac or Ia-Ac or PSMA ligand-imaging conjugate described herein, and means for separately holding said compositions, such as a container, a separate bottle, or a separate foil box (packet). In another embodiment, a composition comprising one or more of the compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac or PSMA ligand-imaging conjugates described herein is provided in a labeled container providing instructions for the use of the compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac or PSMA ligand-imaging conjugates for patient selection and / or treatment.
[0312] In one embodiment, a sterile injectable solution may be prepared by incorporating a required amount of an active agent in a suitable solvent, if necessary, into one or a combination thereof of the components described above, and then filtering and sterilizing. Typically, a dispersion is prepared by incorporating the active combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac or PSMA ligand-imaging conjugates into a dispersion medium and a sterile vehicle containing any additional component of those described above. For a sterile powder for the preparation of a sterile injectable solution, a preferred preparation method is vacuum drying and freeze-drying to produce a powder of the active component plus any additional desired component from a previously sterile-filtered solution, or the components may be sterile-filtered together.
[0313] The composition may be formulated as a solution, microemulsion, liposome, or other ordered structure suitable for high drug concentrations. The carrier may be a solvent or a dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and a suitable mixture thereof. In one embodiment, suitable fluidity may be maintained, for example, by coating, e.g., by the use of lecithin, by maintaining the required particle size in the case of a dispersion, and by the use of a surfactant.
[0314] Any effective regimen for administering compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac may be used. For example, the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac may be administered as a single dose or as a multi-dose daily regimen with divided doses. Additionally, for example, a staggered regimen of 1 to 5 days per week may be used as an alternative to daily treatment, and for the methods described herein, such intermittent or staggered daily regimens are considered equivalent to daily treatment. In an exemplary embodiment, cancer is treated by administering a combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac to a patient multiple times. In one embodiment, a patient is injected with a combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac multiple times (preferably about 2 to up to about 50 times), for example, at intervals of 12 to 72 hours or 48 to 72 hours. Additional injections of the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac may be administered to the patient at intervals of several days or months after the initial injection, and additional injections may prevent the recurrence of cancer. In another exemplary embodiment, the patient is treated to treat cancer with multiple injections of I-Lu or Ia-Lu following a single injection of compounds I-Lu or Ia-Lu and compounds I-Ac or Ia-Ac in any order of injections on the same day. In some embodiments, the patient is injected with compound I-Lu or Ia-Lu and compound I-Ac or Ia-Ac each at an initial injection on the same day, in any order or simultaneously, for example, at intervals of 12 to 72 hours or at intervals of 48 to 72 hours, or once a week or once every two weeks, followed by multiple injections (preferably up to 2 to 50 times) of compound I-Lu or Ia-Lu.
[0315] Any suitable course of treatment by combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac may be used. In one embodiment, the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered as a single daily dose five days per week during weeks 1, 2, and 3 of each 4-week cycle, and is not administered during week 4. In an alternative embodiment, the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered as a single daily dose three days per week during weeks 1 and 3 of each 4-week cycle, and is not administered during weeks 2 and 4. In an alternative embodiment, the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered twice a week during weeks 1 and 2, i.e., on days 1, 4, 8, and 11 of a 3-week cycle. In an alternative embodiment, the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered once a week during weeks 1 and 2, i.e., on days 1 and 8 of a 3-week cycle. In an alternative embodiment, the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered on a single day, in any order, or simultaneously, after which compound I-Lu or Ia-Lu is administered once a week for about 2 to about 6 cycles. In an alternative embodiment, the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered on a single day, in any order, or simultaneously, after which compound I-Lu or Ia-Lu is administered once a week for about 2 to about 6 cycles, and then the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered on a single day, in any order, or simultaneously, after which compound I-Lu or Ia-Lu is administered once a week for about 2 to about 6 cycles.
[0316] In an alternative embodiment, the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered together in any order within about 2 to 72 hours, followed by the administration of compound I-Lu or Ia-Lu in a cycle once per week for about 2 to about 6 cycles. In an alternative embodiment, the combination of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is administered together in any order within about 2 to 72 hours, followed by the administration of compound I-Lu or Ia-Lu in a cycle once per week for about 2 to about 6 cycles, followed by the administration of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac in any order or simultaneously on a single day, followed by the administration of compound I-Lu or Ia-Lu in a cycle once per week for about 2 to 6 cycles.
[0317] The dosage levels of compounds I-Lu or Ia-Lu, and I-Ac or Ia-Ac, may be measured in GBq and MBq, respectively. In some embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 2 GBq to about 20 GBq. In some embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 2 GBq to about 13 GBq. In some embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 4 GBq to about 11 GBq. In some embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 5 GBq to about 10 GBq. In some embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 6 GBq to about 9 GBq. In some embodiments, the therapeutically effective dose of I-Lu or Ia-Lu is about 6 GBq to about 8 GBq. In some embodiments, the therapeutic effective dose of I-Lu or Ia-Lu is about 6.5 GBq to about 8.5 GBq. In some embodiments, the therapeutic effective dose of I-Lu or Ia-Lu is about 7 GBq to about 8 GBq. In some embodiments, the therapeutic effective dose of I-Lu or Ia-Lu is about 7.4 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is about 15 GBq to about 200 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is about 25 GBq to about 185 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is about 35 GBq to about 150 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is about 40 GBq to about 100 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is about 44 GBq. In some embodiments, the maximum duration of the target treatment is about 19 to 23 months.
[0318] In some embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is 2 GBq to 20 GBq. In some embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is 2 GBq to 13 GBq. In some embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is 4 GBq to 11 GBq. In some embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is 5 GBq to 10 GBq. In some embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is 6 GBq to 9 GBq. In some embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is 6 GBq to 8 GBq. In some embodiments, the therapeutically effective amount of I-Lu or Ia-Lu is 6.5 GBq to 8.5 GBq. In some embodiments, the therapeutic effective dose of I-Lu or Ia-Lu is 7 GBq to 8 GBq. In some embodiments, the therapeutic effective dose of I-Lu or Ia-Lu is 7.4 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is 15 GBq to 200 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is 25 GBq to 185 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is 35 GBq to 150 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is 40 GBq to 100 GBq. In some embodiments, the total dose of I-Lu or Ia-Lu is 44 GBq. In some embodiments, the maximum duration of the target treatment is 19 to 23 months.
[0319] In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 20 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 10 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 4 MBq to about 14 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq to about 10 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 6 MBq to about 8 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq to about 7 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 1 MBq to about 4 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 2 MBq to about 3 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 5 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is about 2.5 MBq.
[0320] In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 1 MBq to 20 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 1 MBq to 10 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 4 MBq to 14 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 5 MBq to 10 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 6 MBq to 8 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 5 MBq to 7 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 1 MBq to 4 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 2 MBq to 3 MBq. In some embodiments, the therapeutic effective amount of I-Ac or Ia-Ac is 5 MBq. In some embodiments, the therapeutically effective amount of I-Ac or Ia-Ac is 2.5 MBq.
[0321] The PSMA ligand-imaging conjugates and compounds I-Lu, I-Ac, Ia-Lu, and Ia-Ac described herein may contain one or more chiral centers, or they may exist as multiple stereoisomers. Accordingly, it will be understood that the present invention comprises pure stereoisomers as well as mixtures of stereoisomers, such as enantiomers, diastereomers, and mixtures rich in enantiomers or diastereomers. The PSMA ligand-imaging conjugates and compounds I-Lu, I-Ac, Ia-Lu, and Ia-Ac described herein may exist as geometric isomers. Accordingly, it will be understood that the present invention comprises pure geometric isomers or mixtures of geometric isomers.
[0322] It is acknowledged that the PSMA ligand-imaging conjugates and compounds I-Lu, I-Ac, and Ia-Lu, Ia-Ac described herein may exist in non-solvent forms as well as solvent forms, including hydrated forms. Generally, solvent forms are equivalent to non-solvent forms and are included within the scope of the present invention. The PSMA ligand-imaging conjugates and compounds I-Lu, I-Ac, Ia-Lu, and Ia-Ac described herein may exist in a number of crystalline or amorphous forms. Generally, all physical forms are equivalent to the uses considered in the present invention and are intended to be within the scope of the present invention.
[0323] In another embodiment, a composition and / or dosage form for the combined administration of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is prepared from compound I-Lu or Ia-Lu and I-Ac or Ia-Ac having a purity of at least about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 99.5%. In another embodiment, a composition and / or dosage form for the combined administration of compound I-Lu or Ia-Lu and I-Ac or Ia-Ac is prepared from compound I-Lu or Ia-Lu and I-Ac or Ia-Ac having a purity of at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%.
[0324] In another embodiment, a composition and / or dosage form for administration of a PSMA ligand-imaging conjugate is prepared from a PSMA ligand-imaging conjugate having a purity of at least about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 99.5%. In another embodiment, a composition and / or dosage form for administration of a PSMA ligand-imaging conjugate is prepared from a PSMA ligand-imaging conjugate having a purity of at least 90%, or at least 95%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%.
[0325] In another embodiment, a composition and / or dosage form for administration of a radiolabeled PSMA ligand-imaging conjugate is prepared from a PSMA ligand-imaging conjugate having a radiochemical purity of at least about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 99.5%. In another embodiment, a composition and / or dosage form for administration of a PSMA ligand-imaging conjugate is prepared from a PSMA ligand-imaging conjugate having a purity of at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%.
[0326] The purity of the compounds I-Lu, I-Ac, Ia-Lu, and Ia-Ac or the PSMA ligand-imaging conjugate described herein can be measured using any conventional technique, including various chromatographic or spectroscopic techniques, such as high pressure or high-performance liquid chromatography (HPLC), nuclear magnetic resonance spectroscopy, TLC, UV absorbance spectroscopy, fluorescence spectroscopy, etc.
[0327] In another embodiment, the compounds I-Lu, I-Ac, Ia-Lu, and Ia-Ac or PSMA ligand-imaging conjugates described herein may be provided in a sterile container or package.
[0328] In one embodiment, the clinical benefit to a patient from the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac may be characterized by overall survival (OS). As used herein, the term “overall survival (OS)” means the time from the date of randomization to the date of death from any cause.
[0329] In one embodiment, the clinical benefit to the patient from treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac can be characterized using the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. For example, the criteria consider the measurement of the longest diameter for all target lesions, first edition WHO Handbook (3)Adopted from: Complete Response (CR) - disappearance of all target lesions; Partial Response (PR) - at least a 30% reduction in the sum of the longest diameters of the target lesions when considering the reference sum of the longest diameters; Stable Lesion (SD) - neither sufficient shrinkage for a partial response nor sufficient increase for a progressive lesion when considering the minimum sum of the longest diameters since the initiation of treatment when considering the reference sum of the longest diameters since the initiation of treatment when considering the minimum sum of the longest diameters recorded since the initiation of treatment when considering the sum of the longest diameters of the target lesions is at least a 20% increase or the appearance of one or more new lesions. In other modalities, the Overall Disease Response Rate (ORR) is a clinical benefit, calculated as the percentage of patients who achieved the best response of CR or PR. The Overall Disease Control Rate (DCR) may be another clinical benefit, calculated as the percentage of patients who achieved the best response of CR, PR, or SD. In some embodiments, the response may be the disease control rate (DCR) as measured by RECIST v1.1 standards.
[0330] In other embodiments, the clinical benefit to patients from treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac may be characterized by radiographic progression-free survival (rPFS). "Radiographic progression-free survival" as described herein means the time from the date of randomization to the date of radiographic disease progression or death from any cause as outlined in the literature [Prostate Cancer Working Group 3 (PCWG3)]. For example, see the literature [Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-resistant Prostate Cancer: Updated Recommendations from the Prostate Cancer Chronic Trials Work Group 3. J Clin Oncol 2016; 34(12): 1402-18]. In other modalities, the clinical benefit to a patient from treatment with I-Lu or Ia-Lu, and I-Ac or Ia-Ac, may be characterized as the time to the first symptomatic skeletal event (SSE). A symptomatic skeletal event will be recognized as meaning a clinically significant pathological fracture, surgery or radiation on the bone, or spinal cord compression. The “time to the first symptomatic skeletal event” as described herein means from the date of randomization to the date of the earlier of the occurrence of the first new symptomatic fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain.
[0331] In one exemplary example, total survival is the time until the death of a given patient, defined as the number of days from the first date the patient received protocol treatment (C1D1) to the date of the patient's death. All issues leading to death may be included, regardless of whether the issue occurred while the patient was still taking the study drug or after the patient discontinued the study drug. If the patient did not die, the data may be censored on the latest of the following dates: the last study visit, the last contact date, or the date the patient was last known to be alive.
[0332] Alternatively, the clinical benefit to the patient as a result of treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is characterized by inhibition of tumor growth, which can be confirmed in the patient, for example, through follow-up imaging of the patient's cancer after treatment with the combination of I-Lu or Ia-Lu and I-Ac or Ia-Ac. For example, inhibition of tumor growth can be characterized by measuring the tumor size in the patient after administration of I-Lu or Ia-Lu and I-Ac or Ia-Ac using any imaging technique described herein, and inhibition of tumor growth is indicated by a stable tumor size or a reduction in tumor size. It will be understood that the identification of inhibition of tumor growth can be achieved using various techniques and is not limited to the imaging methods described herein (e.g., CT, MRI, PET imaging, SPECT imaging, or chest X-ray).
[0333] In one embodiment, a method for determining whether the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is recommended for the treatment of a cancer patient is provided, the method comprising the step of determining the PSMA status in the cancer patient, wherein the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is recommended for the treatment of the patient if the patient's PSMA status is positive.
[0334] In one embodiment, a method is provided for evaluating whether the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is recommended for the treatment of a patient having one of the cancers described herein. The method comprises the step of visually determining the PSMA status in the patient, wherein the PSMA status is based on an imaging tumor that is PSMA-positive in the patient, and the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is recommended for the treatment of the patient when the patient's PSMA status is positive.
[0335] In the embodiments described above, if the patient belongs to the group having a positive PSMA status, clinical benefit of treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac is shown. In one embodiment, the clinical benefit to the patient may be the patient's overall survival, the ability to receive at least four cycles of treatment with the combination of compounds I-Lu or Ia-Lu and I-Ac or Ia-Ac, inhibition of tumor growth, stable lesion, partial response of the patient to treatment, complete response of the patient to treatment, disease control (i.e., the best result obtained is a complete response, a partial response, or a stable lesion), and / or total disease response (i.e., the best result obtained is a complete response or a partial response). In one exemplary example, the clinical benefit to a patient being treated for pleural mesothelioma or adenocarcinoma (e.g., adenocarcinoma of the gastroesophageal junction) is a stable lesion.
[0336] In other embodiments, the method described herein includes the following examples. The examples further describe additional features of the various embodiments of the invention described herein. However, it will be understood that the examples are illustrative and are not to be interpreted as limiting other embodiments of the invention described herein. Additionally, it is recognized that other variations of the examples are included in the various embodiments of the invention described herein. Furthermore, as described in relation to various embodiments, it will be understood that all ranges described herein are illustrative and are not intended to be limiting. Those skilled in the art will understand that all ranges described by lower and upper limits, such as about 1 to about 20, include all possible values included in the upper and lower limits and include all possible value ranges available in the set of possible values included in the lower and upper limits.
[0337] Examples
[0338] Example 1:
[0339] In patients with PSMA-positive scans, a single dose of Compound Ia-Ac, 7.4 GBq, and Compound Ia-Lu will be administered on Day 1 for Clinical Therapy Cycle 1, followed by administration every 6 weeks for up to 5 cycles. Subjects will be reviewed weekly for the evaluation of adverse events (onset, duration, grade, and relationship to treatment) only during Cycle 1. DLT is determined by AE only during Cycle 1.
[0340] Subjects are recalibrated at the end of every two cycles. At each recalibration, patients are evaluated using PSMA PET and fluorinated PET / CT bone scans. Bone disease is assessed in accordance with PCWG23 criteria. PSA is measured at least every two weeks according to institutional practice.
Claims
Claim 1 A composition comprising a compound of the chemical formula I-Lu, wherein the compound of the chemical formula I-Lu is used for the treatment of prostate cancer in a patient in combination with a therapeutically effective amount of a compound of the chemical formula I-Ac, 177 It is a compound of the following chemical formula I complexed with Lu, and (I) Here, the compound of chemical formula I-Ac is 225 A compound of formula I complexed with Ac; a therapeutically effective amount of compound I-Lu is 2 GBq to 20 GBq; a therapeutically effective amount of compound I-Ac is 1 MBq to 10 MBq; and a composition in which compound I-Lu and compound I-Ac are administered simultaneously, on the same day, or in any order within 2 to 72 hours.
